Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation. OBJECTIVE: To evaluate the efficacy and safety of risankizumab vs placebo and continuous treatment vs withdrawal in adults with moderate to severe plaque psoriasis. DESIGN, SETTING, A...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Leonardi, Craig L., Gooderham, Melinda, Papp, Kim A., Philipp, Sandra, Wu, Jashin J., Igarashi, Atsuyuki, Flack, Mary, Geng, Ziqian, Wu, Tianshuang, Camez, Anne, Williams, David, Langley, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142813/
https://www.ncbi.nlm.nih.gov/pubmed/32267471
http://dx.doi.org/10.1001/jamadermatol.2020.0723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142813/
https://www.ncbi.nlm.nih.gov/pubmed/32267471
http://dx.doi.org/10.1001/jamadermatol.2020.0723

Ejemplares similares